pipeline-prospector-insert
X

Find Drugs for Otolaryngology (Ear, Nose, Throat) in Preclinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AK-OTOF

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: BofA Securities

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 05, 2020

            Details:

            Akouos' pipeline contains lead candidate AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the otoferlin gene.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GJB2 Gene Therapy

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            Otonomy is currently evaluating a series of compounds being tested for otoprotection against loss of hearing caused by cisplatin (CIHL).